Journal of Clinical Endocrinology & Metabolism, Vol 78, 855-861, Copyright © 1994 by Endocrine Society

ARTICLES

Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men

CJ Bagatell, RH Knopp, JE Rivier and WJ Bremner
Medical Service, Seattle Veterans Affairs Medical Center, Washington 98108.

Premenopausal women have a lower risk of coronary artery disease than men or postmenopausal women; estrogens are thought to contribute to this lower risk. Administration of exogenous estrogen to post- menopausal women increases plasma high density lipoprotein (HDL) cholesterol and may reduce mortality from coronary disease in users. Although many investigations have examined the roles of estrogen in the regulation of lipoproteins in women, little attention has been directed to estrogen regulation of lipids in men. We designed a paradigm to study the role of physiological levels of estradiol (E2) on plasma lipoproteins in healthy men. We used a GnRH antagonist, Nal-Glu, to suppress endogenous steroid hormones in healthy men. We then administered testosterone (T) enanthate (100 mg, im, weekly) to restore T levels to the baseline range, and we administered an aromatase inhibitor, testolactone (Teslac), to prevent the normal conversion of T to E2, thereby producing a selective estrogen deficiency state in normal young men. As controls, we administered Nal-Glu and T along with placebo Teslac to a separate group of men; a third group of men received all placebo medications. We found that in men who received Nal- Glu plus T plus Teslac, E2 levels were profoundly suppressed during treatment, whereas T levels remained in the baseline range. Plasma HDL cholesterol, particularly, the HDL2 fraction, decreased significantly in response to the low serum E2 level. Plasma apoprotein-AI levels also decreased significantly. Plasma LDL and triglyceride levels did not change. All hormone and lipoprotein parameters returned to baseline within 4 weeks after treatment ended. In men who received Nal-Glu plus T, plasma HDL and apoprotein-AI decreased, but these decreases did not achieve statistical significance. Only a small decrease in HDL2 cholesterol was seen in these men. There were no hormonal or lipid changes in the placebo group. We conclude that in men, physiological levels of E2 are important in maintaining plasma levels of HDL cholesterol, especially the HDL2 fraction. These observations suggest that estrogen, in the amount normally produced in men, may offer some degree of protection against cardiovascular disease in males, as they do in women.

This article has been cited by other articles:

				A. C. Casquero, J. A. Berti, A. G. Salerno, E. J. B. Bighetti, P. M. Cazita, D. F. J. Ketelhuth, M. Gidlund, and H. C. F. Oliveira Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice J. Lipid Res., July 1, 2006; 47(7): 1526 - 1534. [Abstract] [Full Text] [PDF]

				J. Q. Purnell, L. B. Bland, M. Garzotto, D. Lemmon, E. M. Wersinger, C. W. Ryan, J. D. Brunzell, and T. M. Beer Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer J. Lipid Res., February 1, 2006; 47(2): 349 - 355. [Abstract] [Full Text] [PDF]

				M. Leblanc, M.-C. Belanger, P. Julien, A. Tchernof, C. Labrie, A. Belanger, and F. Labrie Plasma Lipoprotein Profile in the Male Cynomolgus Monkey under Normal, Hypogonadal, and Combined Androgen Blockade Conditions J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1849 - 1857. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and G. M.C. Rosano Hormonal Regulation of Normal Vascular Tone in Males Circ. Res., December 12, 2003; 93(12): 1142 - 1145. [Full Text] [PDF]

				R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]

				F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]

				A. W. van den Beld, M. L. Bots, J. A. M. L. L. Janssen, H. A. P. Pols, S. W. J. Lamberts, and D. E. Grobbee Endogenous Hormones and Carotid Atherosclerosis in Elderly Men Am. J. Epidemiol., January 1, 2003; 157(1): 25 - 31. [Abstract] [Full Text] [PDF]

				C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524. [Abstract] [Full Text] [PDF]

				Estrogen: Consequences and Implications of Human Mutations in Synthesis and Action J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4677 - 4694. [Abstract] [Full Text]

				K. Sudhir and P. A. Komesaroff Cardiovascular Actions of Estrogens in Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3411 - 3415. [Full Text] [PDF]

				D. E. Cummings, N. Kumar, C. W. Bardin, K. Sundaram, and W. J. Bremner Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4212 - 4219. [Abstract] [Full Text]

				J. P. Bilezikian, A. Morishima, J. Bell, and M. M. Grumbach Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency N. Engl. J. Med., August 27, 1998; 339(9): 599 - 603. [Full Text] [PDF]

				K. Sudhir, T. M. Chou, K. Chatterjee, E. P. Smith, T. C. Williams, J. P. Kane, M. J. Malloy, K. S. Korach, and G. M. Rubanyi Premature Coronary Artery Disease Associated With a Disruptive Mutation in the Estrogen Receptor Gene in a Man Circulation, November 18, 1997; 96(10): 3774 - 3777. [Abstract] [Full Text]